{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-063046","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2026-09-22T20:22:14+00:00","discovered_at":"2026-09-22T20:23:01.749460+00:00","generated_at":"2026-09-22T20:23:09.303728+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vistagen reports positive OLE data from PALISADE-4; LSAS improved 31.4 pts at month 4","bullets":["Safety: N=322; discontinuation due to AEs 1.6% (5/322), no fasedienol-related serious AEs; headache most common TEAE (18.0%).","LSAS mean improvement from baseline 99.3: 20.2 pts (M1), 24.6 (M2), 29.1 (M3), 31.4 (M4); 65% achieved ≥20-pt gain by M4.","SPIN mean improvement from baseline 48.5: 10.5 pts at M1, 14.9 pts at M4; 59% had ≥10-pt improvement.","Company plans FDA meeting this quarter to discuss proposed new registrational Phase 3 trial of fasedienol for social anxiety disorder.","Treatment well-tolerated up to 6x/day as-needed for 12 months; no new safety signals on labs, ECGs, or vitals."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-063046","json":"https://secwatch.observer/filing/0001628280-26-063046.json","markdown":"https://secwatch.observer/filing/0001628280-26-063046.md","text":"https://secwatch.observer/filing/0001628280-26-063046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026063046/0001628280-26-063046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026063046/vtgn-20260922.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-22T20:23:09.303728+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}